1-(4-aminosulfonylphenyl)-4-ethoxycarbonyl-5-phenyl-1H-pyrazole | 676233-15-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-(4-aminosulfonylphenyl)-4-ethoxycarbonyl-5-phenyl-1H-pyrazole
• 英文别名: ethyl 5-phenyl-1-(4-sulfamoylphenyl)-1H-pyrazole-4-carboxylate
• CAS: 676233-15-1
• 化学式: C₁₈H₁₇N₃O₄S
• 分子量: 371.417
• InChiKey: AEOHDDSSXIHYCK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.36
• 重原子数：
  26.0
• 可旋转键数：
  5.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  104.28
• 氢给体数：
  1.0
• 氢受体数：
  6.0

反应信息

• 作为反应物：
  描述：

  1-(4-aminosulfonylphenyl)-4-ethoxycarbonyl-5-phenyl-1H-pyrazole 在 氢氧化钾 作用下， 以 乙醇 为溶剂， 反应 5.0h， 以83%的产率得到5-Phenyl-1-(4-sulfamoyl-phenyl)-1H-pyrazole-4-carboxylic acid
  参考文献：
  名称：

  4-Substituted 1,5-diarylpyrazole, analogues of celecoxib: synthesis and preliminary evaluation of biological properties

  摘要：

  A number of 5-aryl-1-[4-(methylsulfonyl)-phenyl]-1H-pyrazoles and 4-(5-aryl-1H-pyrazol-1-yl)benzenesulfonamides 3, 4, 5, 6, analogues of the COX-2 selective inhibitor celecoxib (celebrex), were synthesized. In order to verify the effects on the biological properties of certain substituents put on position 4 of the pyrazole nucleus, some of these compounds were screened in vivo for their anti-inflammatory and analgesic activities. Moreover, sodium salts of carboxylic acids 4 were tested in vitro for their platelet anti-aggregating properties. The results of these preliminary biological assays showed that new derivatives are not endowed with improved anti-inflammatory and analgesic properties, in comparison with celecoxib. In addition, docking studies were carried out on the most significative compounds to evaluate their interaction mode at the active site of both COX-1 and COX-2. Some remarks about the SAR of this class of COX-inhibitors are drown out.

  DOI：

  10.1016/s0014-827x(03)00136-8
• 作为产物：
  描述：

  苯甲酰乙酸乙酯 以 乙醇 为溶剂， 反应 3.0h， 生成 1-(4-aminosulfonylphenyl)-4-ethoxycarbonyl-5-phenyl-1H-pyrazole
  参考文献：
  名称：

  新型选择性碳酸酐酶IX抑制剂：二芳基吡唑-苯磺酰胺的合成和药理评价

  摘要：

  碳酸酐酶（CA）IX的表达在缺氧时增加，并且由于与不良预后，肿瘤进展和pH调节相关，因此被提议作为治疗靶标。我们报告了新型的人类碳酸酐酶（hCA）抑制剂4-（5-芳基-2-羟甲基-吡唑-1-基）-苯磺酰胺类的合成和药理学评估。为了模拟这种新的酶抑制剂家族在hCA IX活性位点内的结合模式，进行了分子建模研究。药理研究表明，在参数纳摩尔范围内，hCA IX的抑制力很高。这项研究表明磺酰胺基在间位上的位置1-苯基吡唑的相对于我们的化合物的hCA II的选择性增加了hCA IX。使用阿霉素作为细胞毒剂并在选定的CA IX抑制剂存在下，对乳腺癌MDA-MB-231细胞进行了体外抗增殖筛选。结果表明，用1μMCA IX抑制剂将阿霉素在低氧环境中的细胞毒性效率（以IC 50值表示）恢复到20％的水平。

  DOI：

  10.1016/j.bmc.2012.10.029

文献信息

• Isatin-pyrazole benzenesulfonamide hybrids potently inhibit tumor-associated carbonic anhydrase isoforms IX and XII
  作者：Hany S. Ibrahim、Sahar M. Abou-Seri、Muhammet Tanc、Mahmoud M. Elaasser、Hatem A. Abdel-Aziz、Claudiu T. Supuran

  DOI：10.1016/j.ejmech.2015.09.021

  日期：2015.10

  New series of benzenesulfonamide derivatives incorporating pyrazole and isatin moieties were prepared using celecoxib as lead molecule. Biological evaluation of the target compounds was performed against the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1) and more precisely against the human isoforms hCA I, II (cytosolic), IX and XII (transmembrane, tumor-associated enzymes). Most of the tested compounds efficiently inhibited hCA I, II and IX, with K(1)s of 2.5-102 nM, being more effective than the reference drug acetazolamide. Compounds 11e, 11f, 16e and 16f were found to inhibit hCA XII with Ki of 3.7, 6.5, 5.4 and 7.2 nM, respectively. Compounds lie and 16e, with 5-NO2 substitution on the isatin ring, were found to be selective inhibitors of hCA IX and hCA XII. Docking studies revealed that the NO2 group of both compounds participate in interactions with Asp132 within the hCA IX active site, and with residues Lys67 and Asp130 in hCA XII, respectively. (C) 2015 Elsevier Masson SAS. All rights reserved.